相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
Lennart Tonneijck et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Kidney disease and obesity: epidemiology, mechanisms and treatment
Niels Olsen Saraiva Camara et al.
NATURE REVIEWS NEPHROLOGY (2017)
American Diabetes Association Standards of Medical Care in Diabetes 2017
Payal H. Marathe et al.
JOURNAL OF DIABETES (2017)
Estimation of chronic kidney disease incidence from prevalence and mortality data in American Indians with type 2 diabetes
Pavithra Vijayakumar et al.
PLOS ONE (2017)
Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease
Stephen P. Gray et al.
DIABETOLOGIA (2017)
Cathepsin S Cleavage of Protease-Activated Receptor-2 on Endothelial Cells Promotes Microvascular Diabetes Complications
Santhosh V. R. Kumar et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Diabetic nephropathy: landmark clinical trials and tribulations
Gary C. W. Chan et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Olmesartan Prevents Microalbuminuria in db/db Diabetic Mice Through Inhibition of Angiotensin II/p38/SIRT1-Induced Podocyte Apoptosis
Junhui Gu et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2016)
An autopsy study suggests that diabetic nephropathy is underdiagnosed
Celine Q. F. Klessens et al.
KIDNEY INTERNATIONAL (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Beneficial Effects of Sarpogrelate and Rosuvastatin in High Fat Diet/Streptozotocin-Induced Nephropathy in Mice
Dong-hyun Kim et al.
PLOS ONE (2016)
The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Volker Vallon
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Glomerular Aging and Focal Global Glomerulosclerosis: A Podometric Perspective
Jeffrey B. Hodgin et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial
Dick de Zeeuw et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Renal Biopsy in Type 2 Diabetic Patients
Eugenia Espinel et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Bowen Lin et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Valsartan slows the progression of diabetic nephropathy in db/db mice via a reductiorr in podocyte injury, and renal oxidative stress and inflammation
Guangyu Zhou et al.
CLINICAL SCIENCE (2014)
Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats
Amal Hofni et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Effect of Insulin on ACE2 Activity and Kidney Function in the Non-Obese Diabetic Mouse
Marta Riera et al.
PLOS ONE (2014)
A Novel Mouse Model of Advanced Diabetic Kidney Disease
Jean-Francois Thibodeau et al.
PLOS ONE (2014)
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Diabetic nephropathy in a nonobese mouse model of Type 2 diabetes mellitus
Sandeep K. Mallipattu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach
Crystal A. Gadegbeku et al.
KIDNEY INTERNATIONAL (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Linda F. Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sulodexide Decreases Albuminuria and Regulates Matrix Protein Accumulation in C57BL/6 Mice with Streptozotocin-Induced Type I Diabetic Nephropathy
Susan Yung et al.
PLOS ONE (2013)
Renal Function in Diabetic Disease Models: The Tubular System in the Pathophysiology of the Diabetic Kidney
Volker Vallon et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 74 (2012)
Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model
Cristina Martinez-Garcia et al.
DISEASE MODELS & MECHANISMS (2012)
Add-On Aliskiren Elicits Stronger Renoprotection Than High-Dose Valsartan in Type 2 Diabetic KKAy Mice That Do Not Respond to Low-Dose Valsartan
Bai Lei et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2012)
Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy
David K. Packham et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Glomerular hyperfiltration and increased glomerular filtration surface are associated with renal function decline in normo- and microalbuminuric type 2 diabetes
Tatsumi Moriya et al.
KIDNEY INTERNATIONAL (2012)
Glomerular hyperfiltration: definitions, mechanisms and clinical implications
Imed Helal et al.
NATURE REVIEWS NEPHROLOGY (2012)
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Hans-Henrik Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
Yin Liang et al.
PLOS ONE (2012)
A Glimpse of Various Pathogenetic Mechanisms of Diabetic Nephropathy
Yashpal S. Kanwar et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study
E. Imai et al.
DIABETOLOGIA (2011)
An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes
Sufyan G. Sayyed et al.
KIDNEY INTERNATIONAL (2011)
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pablo E. Pergola et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
Hermann Haller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease
Qingjian Wang et al.
FIBROGENESIS & TISSUE REPAIR (2011)
Renal Failure Increases Cardiac Histone H3 Acetylation, Dimethylation, and Phosphorylation and the Induction of Cardiomyopathy-Related Genes in Type 2 Diabetes
Anil Bhanudas Gaikwad et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria
Sharon G. Adler et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice
A. M. D. Watson et al.
DIABETOLOGIA (2010)
Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice
Yi-Fei Dong et al.
JOURNAL OF HYPERTENSION (2010)
BTBR Ob/Ob Mutant Mice Model Progressive Diabetic Nephropathy
Kelly L. Hudkins et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Avosentan for Overt Diabetic Nephropathy
Johannes F. E. Mann et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model
Asada Leelahavanichkul et al.
KIDNEY INTERNATIONAL (2010)
Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10
Sufyan G. Sayyed et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy
Michele Rossini et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
John J. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes
S. G. Sayyed et al.
DIABETOLOGIA (2009)
Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis
G. M. Magee et al.
DIABETOLOGIA (2009)
Mouse Models of Diabetic Nephropathy
Frank C. Brosius et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice
Atsuko Kamijo-Ikemori et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Late onset of Cc12 blockade with the spiegelmer mNOX-E36-3′PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice
Volha Ninichuk et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats
David L. Feldman et al.
HYPERTENSION (2008)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):: a multicentre, randomised, double-blind, controlled trial
Johannes F. E. Mann et al.
LANCET (2008)
Aliskiren combined with losartan in type 2 diabetes and nephropathy
Hans-Henrik Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice
Volha Ninichuk et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Effect of telmisartan on expression of protein kinase C-alpha in kidneys of diabetic mice
Li-jun Yao et al.
ACTA PHARMACOLOGICA SINICA (2007)
Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: Implications for albuminuria in diabetes
Minghao Ye et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice
Hui John Zhao et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Glomerular changes in the KK-Ay/Ta mouse:: A possible model for human type 2 diabetic nephropathy
T Ito et al.
NEPHROLOGY (2006)
Podocyte hypertrophy, adaptation, and decompensation associated with glomerular enlargement and glomerulosclerosis in the aging rat: Prevention by calorie restriction
JE Wiggins et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice
M Sasaki et al.
LIFE SCIENCES (2004)
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
AH Barnett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat
A Benigni et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Diabetic kidney disease in the db/db mouse
K Sharma et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2003)
Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model
M Nangaku et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in dbldb mice
S Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus - A blood pressure-independent effect
G Viberti et al.
CIRCULATION (2002)
Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type I and type 2 diabetic patients:: The Di.NAS randomized trial
G Gambaro et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2002)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
HH Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and Lisinopril microalbuminuria (CALM) study
CE Mogensen et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
分享论文
